Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ChinaBio® Today Exclusive: Licensing agreement between Laekna Inc. and a Major Pharmaceutical Company

publication date: Jul 9, 2017
Laekna, Inc, a biotechnology company, announced today that it acquires world-wide rights from Novartis for an CYP17 inhibitor (CFG920) for the treatment of prostate cancer.  CFG920 is an oral drug candidate of androgen inhibitor. Novartis has conducted a clinical “proof of concept” study in metastatic castration resistant prostate cancer patients and received positive results. More details....


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital